ELAVL1 and thyroid cancer: In the treatment of non-small cell lung and thyroid cancer progression, CMLD-2 has been shown to be an effective HuR inhibitor that binds competitively to HuR, thereby inhibiting HuR’s cell growth and proliferation-promoting effects and the expression of related genes, increasing apoptosis in tumor cells, and thereby slowing the progression of cancer [165,166].